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Graphical Abstract 
 
Abstract 
A synthetic route to a new class of privileged tri- and tetra-cyclic quinazolines 
containing a medium-sized ring is reported. An expedient synthetic route involving 
nucleophilic aromatic substitution, and sequential Niementowski and BOP-mediated 
ring closures afforded a collection of analogues. The scope of the reaction was 
explored in terms of cyclic and acyclic linkers, ring size and substitution pattern.  
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Introduction 
Quinazolines belong to a privileged class of bioactive small molecules,1 which are 
found in a collection of natural products2 and interact with a variety of important 
biological targets3 including tankyrase-1 protein4 (as a senescence inducer), aswell as 
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various anticonvulsant5 and antifungal targets.6 Most notably, several substituted 
quinazolines act as anti-cancer ATP-competitive kinase inhibitors.7-11 Examples of 
quinazoline containing drugs on the market (Figure 1) include gefitinib (also known as 
Iressa®)12,13 and laptinib14 (for HER2+ / EGFR+ and ER+ advanced breast cancer 
treatment). 
 
Figure 1. Selected examples of quinazoline containing anti-cancer drugs. 
 
As part of a medicinal chemistry research programme, we required a method to 
synthesise medium ring containing oxazepino[5,6,7-de]quinazolines with increased 
Fsp3 (fraction of sp3 hybrid atoms) content as a surrogate measure of complexity, thus 
accessing new 3D pharmacophores with potentially improved solubility and increasing 
the chance of discovering new biologically relevant space.15,16 Medium-ring containing 
molecules are challenging to synthesise due to competing effects arising from loss of 
entropy, Pitzer, Baeyer and transannular strain.17,18 In particular there is a paucity of 
information regarding the synthesis of oxazepino[5,6,7-de]quinazolines, and to date, 
the only four examples have been reported by Bradbury and co-workers19,20 using 
Thorpe-Ingold and pseudo-Thorpe-Ingold cyclisation assistance to prepare 
quinazolines with a 7-membered amide ring junction (Figure 2). Encouragingly, these 
examples showed potent inhibition of both EGFR (epidermal growth factor receptor) 
and erbB2 tyrosine kinase protein phosphorylation. Inhibition of the phosphorylation 
of erbB2 in the MCF7 breast cancer cell line was also demonstrated.21 
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Figure 2. Previously reported synthesis of oxazepino[5,6,7-de]quinazolines and a representative 
example of their associated erbB2 and EGFR tyrosine kinase protein phosphorylation inhibition.  
 
The binding mode and/or a small molecule-erbB2 protein crystal structure have not 
been published on the protein data bank (PDB).22 Comparison with other reported 
small molecule-erbB2 inhibitors crystal structures (PDB codes: 3PP0, 4LRM and 
4G5J) suggested that the N1 nitrogen of the quinazoline would make a hydrogen bond 
accepting contact with the methionine residue in the ATP-dependent active site and 
act as an activity anchor. Encouraged by this, we investigated a concise synthesis of 
a more general class of oxazepino[5,6,7-de]quinazolines using the disconnection 
approach detailed in Scheme 1.  
 
Scheme 1. Proposed disconnection strategy to a new class of oxazepino[5,6,7-de]quinazolines. 
 
It was envisioned to generate diversity15 through the 5-O- attachment position, from 
one of a number of commercially available aminoalcohols. These have been installed 
via SNAr chemistry with preference for O-substitution23 on a suitably functionalised 
fluorobenzonitrile. The quinazoline group could be part-assembled via a number of 
reported 4(3H)-quinazolinone syntheses24,25 such as the Niementowski reaction.26 
The completion of the synthesis relied on identifying a suitable coupling agent for the 
intra-molecular cyclisation27 between a primary or secondary amine group and a 
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heteroaromatic amide in preference to polymeric cyclisation. The non-cyclic reaction 
of an amine and heteroaromatic amide has recently been evaluated with a range of 
amide bond coupling agents.28  
Results and Discussion 
To probe the feasibility of the proposed disconnection strategy we investigated a 
synthetic route to an example quinazoline (3a) as shown in Scheme 2. Using 2-amino-
6-fluorobenzonitrile, an SNAr reaction with a protected amino alcohol afforded the key 
starting material 1a in a modest yield. A Niementowski-type cyclisation of 1a in a 
mixture of formic and sulfuric acid at reflux afforded 2a in sufficient yield to attempt the 
final cyclisation of the secondary amine with the pre-installed amide group. The choice 
of amide bond coupling agent has been shown to be critical to the type of the product 
formed (see HATU vs HBTU),28 and we found that BOP operated in the same manner 
as HBTU to afford 3a in good yield. 
 
Scheme 2. Preparation of oxazepinoquinazoline scaffold 3a. Yields are reported and discussed in 
Tables 1 and 3. 
 
Encouraged by this result, we next looked to explore a diverse range of amino alcohols 
with which to react with 6-fluorobenzonitrile to probe the scope of the tandem 
cyclisation strategy. 
The selection of amino alcohol would probe the parameters of the Niementowski (2) 
and BOP (3) mediated ring closures (Table 3). The previously reported23 SNAr reaction 
of 6-fluoro-2-aminobenzonitrile with a limited selection of aminoalcohols generally 
proceeded in modest to good yields (Table 1).  
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Table 1. Isolated yields for the SNAr reactions.  
 
Entry Amino alcohol Product 1 Yield of 1 (%) 
1a 
 
 
17 
1b 
 
46 
2 
 
 
43 
3 
 
 
78 
4 
 
 
70 
5 
 
 
47a 
6a 
 
 
0 
6b 
 
35 
6 
 
7 
 
 
65 
8 
 
 
53 
9a  
 
n.d.b 
9b 
 
72 
10 
 
 
44 
11 
 
 
25 
Key: a An enriched sample of 1e was obtained with trace amounts of the N-substituted analogue; b An 
inseparable 2:1 mixture of 2-amino-6-(3-aminopropoxy)benzonitrile and 2-amino-6-(3- 
hydroxypropylamino)benzonitrile was obtained. 
 
To aid purification of the diaminonitrile products (1), N-tert-butylcarboxy protection of 
the amino alcohol prior to treatment with sodium hydride was examined. The 
protecting group was smoothly installed under standard conditions. However, the N-
tertbutylcarboxy group was found to be readily cleaved under the reaction conditions 
on both primary and secondary amines (entries 1a, 6a and 9a).  
Comparison of the yields between protected and unprotected amines revealed a 2.5-
fold improvement in yield for the unprotected secondary amine (entries 1a vs 1b). In 
the case of a primary amine vs the protected carbamate (entries 6a vs 6b and 9a vs 
9b) showed that either no desired product could be isolated from the complex reaction 
mixture or a 2:1 inseparable mixture of O- and N- SNAr products resulted. This was 
presumably caused by the increasing acidity of the carbamate NH group, resulting in 
the removal of a proton using sodium hydride, allowing an alternative SNAr reaction 
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pathway for the conjugate base of the hydroxyl group to substitute the ipso fluorine 
atom. Although the Niementowski reaction has been extensively explored and 
reviewed,29-31 details regarding the mechanism are less clear despite the apparent 
simplicity of the reaction components.32,33  
 
Table 2 shows that in our system, portion-wise addition of the organic starting material 
afforded high conversion. However, addition in one portion afforded a similar high 
conversion but proved capricious on scale. The best balance when using small 
quantities of the organic component was found to be to dissolve 2 in formic acid to 
facilitate the drop-wise addition.  
 
Table 2. Optimisation of the Niementowski quinazoline ring synthesis (conversion measured by 1H 
NMR spectroscopy).  
 
Entry Conditions Conversion 
(%) after 2 h 
1 (B1) Addition of 1b from t = 0 min 60 
2 (B2) Portion-wise addition of 1b 63 
3 (B3) Portion-wise addition of 1b in formic 
acid 
72 
Key: B1, B2, B3 general conditions are detailed in the accompanying ESI. 
 
During the course of our studies into the Niementowski ring closure reaction and 
subsequent functionalization we observed the formation of an amide by-product (e.g. 
4b), either resulting from acid-mediated hydrolysis by adventitious water or as a 
reaction intermediate. Of note, re-submission of the amide (4b) to the reaction mixture 
yielded the Niementowski product (2b), giving further support to the most recent 
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enquiry into the mechanism which demonstrated that a benzamide intermediate 
formed via a slower reaction pathway.33 
Furthermore we noted during our optimisation studies (Table 2) that the reaction 
proceeded in higher yield in a sealed system (a crimped microwave vial) in comparison 
to a round bottom flask under an inert atmosphere.34 We therefore, designed an 
experiment to explore if the Niementowski reaction is in fact a carbon monoxide-
mediated reaction. The literature was found to be inconsistent in terms of parameters 
such as portion-wise addition of starting materials, sealed or open reaction vessels 
and having the mixed acids heated to reflux prior to addition of the organic starting 
component. The possibility that the aminobenzamide formed from acid-catalysed 
hydrolysis of the benzonitrile35 which in turn may intercept carbon monoxide was 
intriguing. It has been reported36-40 that under particular conditions both CO2 and CO 
could be sequestered by an aminobenzamide to form a quinazoline-2,4(1H,3H)-dione. 
In our hands, usinf a model system (anthranilamide) under 1 atmosphere of CO in 
refluxing sulfuric acid no evidence of ring closure was observed for the Niementowski 
reaction. 
Our attention turned next to the generality of the tandem Niementowski and BOP 
mediated sequential ring closures of 1 to give 3 (via 2) and are reported in Table 3. 
Despite the improvements in yield shown in Table 2, in some cases purification (flash 
silica gel and/or ion-exchange chromatography) remained an issue and therefore 
telescoping the Niementowski product (2) after isolation, but not purification, onto the 
BOP-mediated ring closure, improved the two-step yield as shown in Table 3.  
 
 
 
 
 
 
 
 
9 
 
Table 3. Tandem cyclisation reactions.  
 
Entry Substrate Conditions Yield of 2a-m 
(%)a 
Product 3 Yield of 3a-m (%)b 
1a 
  
B1 14% 
 
71% 
1b B2 83% 65% 
1c B3 80% 66% 
2 
  
B3 35%c 
 
52% 
(18%, 2 steps) 
3 
  
B3 - 
 
60% (2 steps) 
4 
  
B3 55% 
 
89% 
(49%, 2 steps) 
5 
  
B3 - 
 
25% (2 steps) 
6 
  
B3 - 
 
70% (2 steps) 
10 
 
7 
  
B3 - 
 
<5% conversiond 
8 
  
B3 - 
 
32% (2-steps) 
9 
  
B3 99% (80% 
purity) 
  
0%d,e 
10 
  
B3 - 
 
<5% conversiond 
11 
 
B3 0%a - - 
Key: B1, B2 or B3 refer to the Niementowski conditions as described in Table 2 and the ESI; a Purified 
and isolated yield for intermediates 2; b Purified and Isolated yield for products 3; c Terminating the 
reaction at t = 30 min led to isolation of the amide intermediate (4b);  d Decomposition products were 
observed; e The benzotriazole reaction intermediate (5i), amongst others, was observed. 
 
As the original structure 3a41 (entries 1a-c) was based on a cyclic amino alcohol, we 
sought to investigate whether this group could be varied in size (changing piperidine 
to pyrrolidine; entries 1 and 2) which gratifyingly proceeded in good yield. We also 
probed whether a pseudo-Thorpe-Ingold effect of an α-ring system encouraged a 7-
ring cyclisation. Removal of the piperidine ring system to give the alkyl chain 
secondary amino alcohol (entries 1 vs 3) gave an analogous yield of the ring closure 
product.  
 
Thus far, only secondary amines were used (entries 1-5). To probe whether primary 
amines were also suitable (entries 6-11) these were also subjected to the tandem 
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cyclisation strategy with mixed results. For instance the Thorpe-Ingold assisted 
product 3h (entry 8) proceeded in a modest 32% yield over two-steps. Contrary, to the 
data obtained in the secondary amine system (entries 3 vs 1 and 2) removal of one 
methyl group in the primary amine system (entry 7), only showed trace conversion to 
product. Moving the methyl group adjacent to the oxa-position was also detrimental to 
the reaction success (entry 10). However, the unsubstituted alkyl chain in entry 6 
proceeded in excellent yield over two-steps. 
 
The formations of 8 membered and above ring systems are significantly more 
challenging targets in synthesis. By drawing analogy with the linear alkyl chain 
example, homologated amino alcohols (entries 4 and 9) would deliver the comparison 
to the 7-ring (entries 1 and 6). Molecular mechanics (MM2) optimisation of the 
structures suggested the 8-ring system would be the limit of accessible cyclisation 
conformations when fused to a bicyclic quinazoline ring system. To our delight, the 
tetracyclic 8-ring system (entry 4) formed in excellent yield. However, the acyclic 
analogue (entry 9) failed to deliver the desired cyclic product. The dichotomy in 
conversion between the acyclic and cyclic amino examples may be a result of the now 
accentuated difference in pseudo Thorpe-Ingold effects between the α-H and α-ring 
systems. Intriguingly, investigation of the reaction mixture revealed the presence of 5i 
confirming the postulated reaction mechanism (Scheme 3).28 
 
 
Scheme 3. A limitation of the methodology and 1H NMR spectroscopic observations of reaction 
intermediate 5i. 
 
A probe compound (entry 11) was attempted to form a more strained product. 
However, this did not afford the desired Niementowski reaction product and instead 
degradation was observed. It was also found that neither 2- nor 4-aminocyclohexanol 
afforded the Niementowski intermediate. 
12 
 
Finally, to demonstrate the possibility of examples of N-substitution at the 4-position 
which did not use H or methyl, a phenyl example was introduced (entry 5) in good 
yield.  
Evidence for the desired transformation from the quinazolin(4H)one (2)42 to give the 
cyclised 4-aminoquinazoline (3)43 was gathered not only from the loss of the amide 
carbonyl peak but also the diagnostic downfield shift of the H2 proton as detailed in 
Table 4, indicating connection of the aliphatic amino termini to the activated 
quinazolin(4H)one ring system (3).  
 
Table 4. Downfield shift of the diagnostic singlet aromatic proton H2 signal upon cyclisation of 
secondary amine examples of 2 as measured by 1H NMR spectra. 
Starting 
material 
Product ±ppm 
2a 3a +0.35 
2b 3b +0.21 
2c 3c +0.39 
2d 3d +0.19 
2e 3e +0.27 
 
Representative examples of the final compounds (3a-d, 3f and 3h) were tested for 
anti-proliferative effects using MCF7, BT474 and MDA-MB231 breast cancer cell lines, 
however none showed effects in the submicromolar range.44 Further development of 
this new compound class and its application to other biological targets are currently 
underway and will be reported in due course. 
Conclusions 
In the present study, we have identified a straightforward three-step route to a new 
class of oxazepino and oxazecino quinazolines. We have demonstrated the SNAr of a 
fluorobenzonitrile with a range of commercially available aminoalcohols followed by 
sequential Niementowski and BOP-mediated ring closure to afford a collection of 
rigidified analogues. This remarkable tandem cyclisation strategy is a new and 
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enabling route to rigidify kinase inhibitor-like quinazolines and has wide-ranging 
potential in the field of medicinal chemistry. 
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(dd, J = 8.5, 1.0 Hz, 1H), 4.48 (s, 2H), 3.96 (dd, J = 9.0, 3.7 Hz, 1H), 3.86 (dd, 
J = 9.0, 8.0 Hz, 1H), 3.14 (ddt, J = 11.5, 4.0, 2.0 Hz, 1H), 3.10 – 2.97 (m, 1H), 
2.78 (s, 1H), 2.71 (td, J = 11.9, 2.7 Hz, 1H), 1.96 – 1.78 (m, 1H), 1.76 – 1.62 
(m, 2H), 1.58 – 1.26 (m, 3H); 13C NMR (126 MHz, CDCl3) δ = 161.0, 151.1, 
134.5, 115.4, 107.6, 100.4, 86.7, 73.0, 55.4, 46.4, 28.3, 25.9, 24.1; LC-MS 
(TOF, 2.0 min) Rt = 0.59 min; m/z (ESI) 232 (M+H); Hi-Res LC-MS (ESI) m/z 
calcd for C13H18N3O (M+H) 232.1450, found 232.1452. 2-Amino-6-(piperidin-2-
ylmethoxy)benzonitrile (1a) (87 mg, 0.38 mmol) was added portion-wise to a 
refluxing mixture of formic acid (1.5 mL, 39.1 mmol) and conc. sulphuric acid 
(0.09 mL, 1.7 mmol). 30 min after the last addition, the mixture was cooled to 0 
oC and poured onto ice-water. The aqueous was made basic with satd. 
NaHCO3 (aq.) and extracted with ethyl acetate (20 mL x 3). The organic layer 
was dried over sodium sulphate, filtered and the solvent removed in vacuo. 
Purification by ion-exchange chromatography [SCX-2, ammonia-methanol, 2M] 
afforded the corresponding product (2a) as a clear oil (81 mg, 0.31 mmol, 83%). 
νmax/cm-1 2923, 1630, 1603, 1578, 1472 and 1461; 1H NMR (500 MHz, 
CD3OD) δ = 8.05 (s, 1H), 7.65 (dd, J = 8.0 Hz, 1H), 7.22 (dd, J = 8.0, 1.0 Hz, 
1H), 6.98 (dd, J = 8.0, 1.0 Hz, 1H), 4.21 (dd, J = 9.0, 3.5 Hz, 1H), 3.86 (t, J = 
9.0 Hz, 1H), 3.20 – 3.06 (m, 2H), 2.76 (td, J = 12.0, 2.9 Hz, 1H), 1.93 – 1.81 
(m, 1H), 1.81 – 1.63 (m, 2H), 1.50 (dddd, J = 25.1, 12.6, 8.0, 3.7 Hz, 2H), 1.35 
(tdd, J = 12.6, 11.1, 3.8 Hz, 1H); 13C NMR (126 MHz, CD3OD) δ = 163.7, 159.1, 
151.3, 148.5, 134.1, 118.4, 112.6, 109.2, 72.9, 55.3, 45.4, 27.2, 25.0, 23.6; LC-
MS (TOF, 2.0 min) Rt = 0.16 min; m/z (ESI) 260 (M+H); Hi-Res LC-MS (ESI) 
m/z calcd for C14H18N3O2 (M+H) 260.1399, found 260.0805. A round-bottom 
flask was charged with 5-(2-piperidylmethoxy)-3H-quinazolin-4-one (2a) (80 
mg, 0.31 mmol, 1.0 eq.) and (benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) (1.3 eq.) 
before the addition of anhydrous acetonitrile (2.5 ml). DBU (2.5 eq.) was added 
dropwise whilst stirring at 0 °C. The reaction mixture was stirred at 0 °C for a 
further 5 min and then at r.t. for 19 h. The reaction mixture was evaporated and 
the residue purified by flash column chromatography [SiO2, EtOAc:Petrol, 50-
80%] to afford the title compound 3a as a yellow oil (53 mg, 0.22 mmol, 71%). 
νmax/cm-1 2923, 1630, 1603, 1578, 1472 and 1461; 1H NMR (500 MHz, 
CD3OD) δ = 8.40 (s, 1H), 7.62 (dd, J = 8.0 Hz, 1H), 7.37 (dd, J = 8.3, 1.3 Hz, 
1H), 7.04 (dd, J = 7.9, 1.3 Hz, 1H), 5.28 – 5.20 (m, 1H), 4.41 (dd, J = 13.2, 2.8 
Hz, 1H), 4.30 (dd, J = 13.3, 5.5 Hz, 1H), 3.90 (ddt, J = 10.7, 5.1, 2.5 Hz, 1H), 
3.01 (td, J = 12.9, 2.4 Hz, 1H), 2.00 (dtd, J = 10.1, 4.1, 2.3 Hz, 1H), 1.91 – 1.55 
(m, 5H); 13C NMR (126 MHz, CD3OD) δ = 159.9, 158.9, 157.6, 153.9, 132.6, 
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